Welcome to our dedicated page for Pds Biotechnology news (Ticker: PDSB), a resource for investors and traders seeking the latest updates and insights on Pds Biotechnology stock.
PDS Biotechnology Corporation reports developments in targeted cancer immunotherapies based on its Versamune platform. Company news centers on PDS0101, also called Versamune HPV, in HPV16-positive head and neck cancer, and on PDS01ADC, an IL-12 fused antibody drug conjugate and tumor-targeted immunocytokine evaluated across multiple solid tumor indications.
Recurring updates include clinical-trial data, National Cancer Institute-led study presentations, FDA and IND protocol communications, scientific publications, patent coverage for core technology, quarterly financial results, and broader corporate-program updates.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced promising preclinical data for its COVID-19 vaccine candidate, Versamune-CoV-2 (PDS0203). The data show that PDS0203 effectively induces both CD8 killer and CD4 helper T-cells, leading to a 30-45 fold increase in COVID-19 specific T-cells and a 20-25 fold increase in neutralizing antibodies within 14 days. The vaccine demonstrates potential for long-lasting immunity, with effects continuing beyond 30 days. The company also initiated preclinical development for a second candidate, Versamune-CoV-2FC (PDS0204), in partnership with Farmacore Biotechnology.
PDS Biotechnology Corporation (Nasdaq: PDSB) has entered a co-development agreement with Farmacore Biotechnology to accelerate the development of the Versamune®-CoV-2FC vaccine designed to prevent COVID-19. The Brazilian Ministry of Science, Technology, Innovation and Communication will provide initial funding support. This partnership aims to advance the vaccine to Phase 1 clinical trials in Brazil and leverages the Versamune® T-cell activating technology alongside a recombinant SARS-CoV-2 protein. Commercialization rights are retained by Farmacore in Latin America.
PDS Biotechnology Corporation (Nasdaq: PDSB) has announced the dosing of the first patient in a Phase 2 clinical trial for PDS0101, targeting advanced HPV-associated cancers. Conducted by the National Cancer Institute (NCI), the study evaluates a combination of PDS0101 with Bintrafusp alfa and NHS-IL12 in approximately 35 patients. Initial safety and objective responses will be assessed from the first eight patients. This trial aims to enhance the efficacy of PDS0101 through the Versamune® platform, demonstrating its potential in improving outcomes for patients with advanced cancers.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced the publication of an abstract on preclinical studies of PDS0102 at the ASCO Virtual Scientific Program, indicating the Versamune® platform's efficacy in inducing strong killer T-cell responses across various tumors. The study shows that PDS0102, targeting prostate and breast cancers, can activate T-cells that specifically attack cancer cells expressing the TARP protein, associated with an anticipated 450,000 diagnoses this year. These findings demonstrate the potential versatility and effectiveness of the Versamune® technology in immuno-oncology.
PDS Biotechnology Corporation (PDSB) reported its financial results for Q1 2020, showing a net loss of approximately $4.0 million, or $0.39 per share, compared to a net income of $6.8 million in Q1 2019. Research and development expenses increased by 91% to $1.9 million while general and administrative expenses decreased by 47% to $2.1 million. The company initiated vaccine development for COVID-19 and influenza, and secured a U.S. patent for its Versamune® platform. As of March 31, 2020, PDSB held approximately $21.0 million in cash, including net proceeds from a public offering in February.
Summary not available.